Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) announced the publication of new data highlighting the tumor-killing potential of its lead phosphatidylserine (PS)-targeting antibody bavituximab in combination with an agent that induces apoptosis, or programmed cell death...
More...